secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0000950170-25-107617
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma Q2 revenue $15.7M, neffy volume +180% QoQ, net loss $44.9M
---------------------------------------------------------------------

- Total revenue $15.7M, including $12.8M neffy U.S. net product revenue and $2.6M milestone from ALK.
- Net loss of $44.9M ($0.46/sh); SG&A $54.3M driven by DTC campaign; cash $240.1M.
- neffy weekly script volumes grew ~180% from Q1 end to Q2 end; 93% commercial coverage achieved.
- EUR neffy approved in UK and launched in Germany; $5M milestone triggered from ALK.
- Phase 2b urticaria trial initiated; topline data expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/0000950170-25-107617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/spry-20250813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer